Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study
Pirfenidone use may be associated with a reduced lung cancer risk in patients with IPF.
Authors
- Hee‐Young Yoon (ORCID: https://orcid.org/0000-0001-7109-1374)
- Hoseob Kim (ORCID: https://orcid.org/0000-0003-3063-8024)
- Jin Woo Song (ORCID: https://orcid.org/0000-0001-5121-3522)
- Yoonjong Bae
Institutions
- Ulsan College (KR)
- Soonchunhyang University Hospital Seoul (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Hanmi Pharmaceutical (South Korea) (KR)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1183/13993003.01484-2024
- Citations
- 15
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 6.28
Funders
- National Research Foundation of Korea